Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 2
---
='center'>SUBJECT TO COMPLETION, DATED August 8, 2025</div>

PROSPECTUS

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

Up to 9,615,385 Shares of Common Stock
Offered by the Selling Stockholders</div>

This prospectus relates to the resale from time to
time by the selling stockholders named in this prospectus (collectively, the “Selling Stockholders”) or their permitted transferees
(after the expiration of any applicable lock-up period, assuming the satisfaction of any applicable vesting conditions and subject to
the beneficial ownership and stock exchange limitations described herein), of up to 9,615,385 shares of our Common Stock issuable upon
the conversion of the outstanding shares of our Series D Preferred Stock, par value $0.0001 per share (the “Series D Preferred Stock”),
purchased by certain investors pursuant to the Securities Purchase Agreement, dated April 21, 2025, by and among us and such investors,
as amended as of June 25, 2025 (collectively, the “Fourth Securities Purchase Agreement”), with a stated value of $1,000 per
share of the Series D Preferred Stock, converted at the floor price of $3.12 per share of Common Stock (the “Floor Price”),
as adjusted for the reverse stock split effected on June 13, 2025 pursuant to which every 20 shares of Common Stock outstanding as of
immediately prior thereto were converted into one share of Common Stock. Notwithstanding the foregoing, because the Alternate Conversion
Price (as defined in the Series D Certificate of Designations (as defined herein)) changes daily, we have elected to register the number
of shares of Common Stock equal to 300% of the maximum number of shares of Common Stock issuable upon conversion of the Series D Preferred
Stock at the Floor Price. For more information about the Common Stock offered for resale by the Selling Stockholders pursuant to this
prospectus, including the purchase prices paid by such Selling Stockholders for their securities, see “Information Related to Offered
Securities” beginning on page 4 of this prospectus.

The shares of our Common Stock being registered
for resale represent a considerable percentage of our public float, and the sales of such shares, or the perception that these sales could
occur, could cause the market price of the Common Stock to decline significantly. In addition, we will